OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36 th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain ...
IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)—The IKF-IMMULAB trial. Trastuzumab ...
In a study published in Angewandte Chemie International Edition, a research team integrated activity-based protein profiling (ABPP) data with the covalent DNA-encoded chemical library (CoDEL) ...
For the first time, scientists have identified promising drug candidates that bind irreversibly with a notoriously undruggable cancer protein target, permanently blocking it. Transcription factors are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results